查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848002

獸用抗菌藥物敏感性檢測市場按檢測類型、動物類型、最終用戶、病原體類型、樣品類型和產品類型分類－2025-2032年全球預測

Veterinary Antimicrobial Susceptibility Testing Market by Test Type, Animal Type, End User, Pathogen Type, Sample Type, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用抗菌藥物敏感性測試市場規模將達到 2.2188 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2024 1.1338億美元
預計年份：2025年 1.2333億美元
預測年份：2032年 2.2188億美元
複合年成長率 (%) 8.75%

將獸用抗菌藥物敏感性檢測置於臨床實踐、實驗室操作和更廣泛的「同一健康」理念框架下進行考慮，以指導及時、負責任的干涉措施。

獸醫學中抗菌藥物抗藥性的演變迫切需要實證醫學的指導，以闡明診斷檢測在維持治療效果、保護動物和公眾健康方面的作用。獸醫抗菌藥物敏感性檢測處於臨床決策、監測和監管的交匯點，其有效應用會影響治療結果、抗菌藥物管理計劃以及新出現的抗藥性機制的檢測。隨著診斷能力的進步，實驗室和臨床醫生必須採用能夠在臨床上可接受的時限內提供可靠且可重複結果的工作流程和技術。

這種實踐轉變體現了獸醫實踐的異質性，涵蓋了從服務於畜牧業的高性能診斷實驗室到伴侶動物診所和水產養殖場的照護現場檢測。動物類型生物學、樣本基質和病原體多樣性的差異帶來了獨特的分析挑戰，需要量身定做的方法和解讀標準。因此，實驗室主任和政策制定者在選擇檢測平台和通訊協定時，必須權衡準確性、週轉時間、成本和法規遵循。

此外，分子方法與表現型檢測的結合正在顯著改變診斷管道。雖然傳統的肉湯微量稀釋法和紙錠擴散法仍然是解讀表現型藥敏感性的臨床標準，但分子方法能夠快速檢測抗藥性決定簇和與疫情相關的基因型。這種應用凸顯了獸醫、微生物學家、流行病學家和產業夥伴之間進行多學科合作的迫切需要，以便將診斷創新轉化為抗菌藥物管理和動物健康的持續改進。

技術創新、監管演變和數位整合如何重塑獸醫易感性檢測並加速臨床和監測能力的發展

獸醫抗菌藥物敏感性檢測的變革性轉變反映了技術創新、監管預期變化以及不斷發展的臨床需求，這些因素共同重塑了診斷流程。自動化系統提高了檢測通量和標準化程度，使實驗室能夠在擴大營運規模的同時，降低藥敏結果判讀的差異性。同時，快速分子技術和新一代定序技術拓展了我們檢測抗藥性決定因素和追蹤傳播途徑的能力，提高了監測能力，並為有針對性的干涉措施提供了依據。

數據管理軟體和整合資訊平台支援一致的解讀、報告和長期監測。這些工具有助於匯總不同地點和物種的藥敏數據，從而加強區域和國家層面的抗菌藥物管理工作。同時，監管機構和專業學會正在提供更完善的解讀和驗證標準指南，要求實驗室重新評估其工作流程，並確保符合不斷發展的品質框架。

經濟和營運壓力正在推動市場行為的轉變。終端用戶要求解決方案能夠兼顧準確性、速度和成本效益，促使產品種類日益豐富，包括自動化儀器、桌上型系統和模組化試劑套件。因此，製造商和服務供應商越來越注重互通性、遠端支援以及能夠滿足獸醫檢測環境實際需求的客製化試劑系統。這些轉變共同推動著一個更互聯、反應迅速的診斷生態系統的形成，從而能夠同時支持臨床診療和公共衛生目標。

評估2025年關稅調整對診斷設備、耗材和實驗室供應鏈韌性的營運和採購影響

2025年生效的關稅調整為國際診斷設備、耗材和試劑採購領域的相關人員帶來了新的挑戰。部分進口檢測設備和組件關稅的提高，造成了成本壓力，影響獸醫診斷實驗室、設備製造商和耗材經銷商的籌資策略。這種不斷變化的經濟環境迫使檢測機構重新評估供應商關係、庫存策略和資本支出計劃，以減輕短期預算影響。

為此，多家檢測實驗室和終端用戶正盡可能優先選擇在地採購，實現供應鏈多元化，並與區域製造商合作，以減輕關稅波動的影響。這加速了關於區域製造能力以及關鍵耗材（例如肉湯微量稀釋板、紙片擴散法耗材和分子檢測試劑）本地化的討論。同時，採購團隊正在評估包括物流、清關和潛在延誤在內的總擁有成本，並將這些成本納入採購週期和服務等級協議中。

在供應商方面，製造商正在探索各種策略性應對措施以維持市場進入，例如部分本地化生產、價格回扣和配套服務。這些措施旨在透過最大限度地減少直接成本轉嫁給最終用戶，從而維持自動化系統和分子平台的普及率。值得注意的是，關稅環境凸顯了在檢測設施採購流程中建立更完善的風險評估框架的必要性，強調製定應急計劃和採取協作方式，以在應對財務限制的同時保障研究的連續性。

揭示檢測方式、物種特定需求、最終用戶、病原體多樣性、樣本基質和產品類型如何共同決定診斷優先事項和投資策略。

細分市場層面的動態揭示了不同的檢測方式、動物群、終端用戶、病原體組、樣本基質和產品類型如何影響診斷需求和創新重點。檢測類型分為自動化系統、肉湯微量稀釋法、紙錠擴散法、ETEST 和分子檢測法，其中自動化檢測又根據平台進一步細分，包括 MicroScan、PHOENIX、VITEK 和 WalkAway 系統。肉湯微量稀釋法分為自動化和手動兩種形式，分子檢測包括基於 LAMP 的方法、基於 NGS 的策略、PCR 和 qPCR，每種方法在速度、靈敏度和資訊深度之間各有優劣。

涵蓋的動物類型包括水產養殖動物、伴侶動物、馬匹、牲畜和家禽，重點闡述了疾病流行率、飼養方式和法律規範在不同動物類型中的差異，以及這些差異如何影響檢測流程。最終用戶涵蓋製藥和生物技術公司、研究機構、動物診斷實驗室以及獸醫醫院和診所，每個相關人員都有其獨特的優先事項：製藥開發商重視用於藥物開發的標準化藥敏試驗數據；研究機構專注於檢測方法開發和流行病學研究；診斷實驗室優先考慮檢測通量和品管；而臨床機構則需要快速、可操作的結果。

病原體類型分為真菌、革蘭氏陰性菌、革蘭氏陽性菌和分枝桿菌，每種病原體都需要不同的檢測組合、判讀標準和隔離方法。檢體類型，例如血液、牛奶、檢體、組織和尿液，會帶來不同的分析前挑戰，影響檢測方法的選擇和驗證的必要性。產品類型涵蓋儀器、試劑套件和軟體服務。儀器進一步分為自動化系統和桌上型系統，試劑套件分為耗材和試劑，軟體服務分為資料管理軟體和技術支援諮詢。這些細分領域的交集導致了不同的投資模式、檢驗要求和打入市場策略，凸顯了模組化產品設計、穩健的供應鏈和有針對性的客戶支援對於滿足獸醫診斷行業多樣化需求的重要性。

區域診斷技術的應用將受到美洲、歐洲、中東和非洲以及亞太地區基礎設施、法律規範和特定動物類型優先事項的驅動。

區域模式清晰地表明，地理位置、監管環境和產業基礎設施如何影響抗菌藥物敏感性檢測解決方案的採用。在美洲，先進的實驗室網路和成熟的獸醫臨床實踐支持自動化設備和整合資訊技術的早期應用，而區域性舉措則側重於監測數據匯總和管理項目，將臨床實驗室與公共衛生系統連接起來。在伴侶動物和畜牧業領域，獸醫診斷的投資均有所增加，這主要得益於私人檢測實驗室的整合以及針對特定行業的監管關注。

在歐洲、中東和非洲，統一的監管環境和實驗室認證框架催生了對標準化檢測方案和可互通資料系統的需求。北歐和西歐市場正日益採用分子診斷和自動化平台，並輔以完善的監測基礎設施；而中東和非洲則優先考慮可擴展、經濟高效的解決方案，以應對物流限制和不同養殖系統中物種的多樣性。

亞太地區是一個充滿活力的地區，這得益於其蓬勃發展的農業產業，製造業產能不斷成長，並高度重視水產養殖和畜牧業診斷。部分市場的快速都市化和伴侶動物數量的增加，也推動了對臨床級診斷產品的需求。在這些全部區域，跨境貿易、在地化生產以及不斷變化的監管要求，迫使製造商和檢測實驗室採用靈活的分銷模式和本地化支援策略，以確保檢測品質的穩定性和供應的可靠性。

供應商如何將檢驗的平台、本地化支援和整合數據分析相結合，以提供可靠的診斷解決方案和建立長期的客戶夥伴關係

獸用抗菌藥物敏感性檢測領域的領導者憑藉其廣泛的平台、地理覆蓋範圍和服務能力脫穎而出，這些優勢既能滿足常規診斷需求，也能滿足複雜的監測要求。檢驗的自動化儀器與強大的試劑供應鏈和數據管理軟體結合的製造商，能夠更好地支援尋求標準化工作流程的高效能實驗室。同時，投資於模組化桌上型平台和專用試劑套件的公司，則能更好地滿足分散式臨床環境和物種特異性檢測需求。

提供服務和支援對於維持儀器運作和確保實驗室間結果判讀的一致性至關重要。技術支援、培訓專案和諮詢服務能夠幫助實驗室進行驗證、品質保證和法規遵循，從而提高客戶維繫並創造長期夥伴關係機會。與研究機構和藥物研發公司的合作能夠進一步加強產品平臺和新方法的推廣，尤其是在應對新出現的抗藥性機制方面。

策略差異化也體現在軟體和分析能力。能夠提供整合數據管理、自動化報告和趨勢分析的供應商，可以幫助檢測實驗室將原始的易感性數據轉化為可供臨床醫生和藥物管理委員會使用的實用資訊。利用夥伴關係關係拓展區域生產和分銷網路的公司，更有能力應對供應鏈中斷和關稅的影響，從而維持市場進入，並確保終端用戶能夠持續獲得檢測服務。

供應商和實驗室可採取切實可行的策略性舉措，以提升診斷效能、供應韌性和整合資料能力，從而支援管理目標的實現。

產業領導者應優先投資於能夠提升診斷準確性、供應鏈穩定性以及可操作數據工作流程的領域，以滿足臨床和監測需求。首先，透過提供高通量自動化系統和靈活的桌上型解決方案，使平台組合與終端用戶的實際操作相契合，能夠幫助供應商應對各種實驗室環境和臨床情況。此外，配備可靠的套件、試劑和品管材料，可降低採用門檻，並確保不同實驗室獲得可重複的結果。

其次，擴大區域製造和物流能力可以減輕關稅相關的成本波動和地緣政治供應中斷的影響。建立區域試劑生產、策略性經銷夥伴和庫存緩衝策略有助於確保檢測服務的連續性。第三，投資資料管理軟體和互通性，透過實現整合報告、趨勢分析和資料共用，增強了對最終用戶的價值提案，從而更好地進行管理和監督。這種方法不僅有助於加強與檢測機構和相關人員的聯繫，還能創造與分析和諮詢服務相關的新收入來源。

最後，產業相關人員應深化與監管機構、專業協會和獸醫網路的合作，以統一檢測方法驗證、解讀標準和報告規範。積極合作將加速創新方法的應用，確保符合不斷更新的指南，並支持將診斷數據轉化為有效的管理政策。綜上所述，這些建議支持一項平衡的策略，該策略強調技術卓越、營運韌性和相關人員合作，以促進永續發展。

採用混合方法，結合專家訪談、技術文獻綜述和產品格局分析，以提供可操作且經過嚴格檢驗的診斷見解。

本研究採用多維度的二級調查方法，結合了對產業專家的質性訪談、文獻綜述和產品格局分析，旨在全面了解獸用抗菌藥物敏感性檢測環境。主要研究內容包括與實驗室主任、臨床獸醫、採購專家和行業高管進行結構化訪談，以了解營運重點、驗證實踐和採購行為。這些訪談著重於洞察實際工作流程以及實驗室在速度、準確性和成本之間權衡取捨。

二次研究查閱了同行評審的科學出版物、監管指導文件和公共監測報告，以確保在說明方法、解釋標準和病原體特異性檢測注意事項方面具有技術準確性。產品格局分析對儀器平台、檢測形式、試劑系統和軟體進行了分類，並繪製了功能和服務模式圖。研究過程中，始終關注驗證要求、品管措施以及不同司法管轄區法律規範的影響。

數據綜合分析結合了定性研究結果、產品分析和區域分析，以識別關鍵趨勢、營運挑戰和策略機會。透過整合來自多個相關人員的觀點，並評估其與已記錄的監管動態和同儕審查證據的一致性，實現了對洞察結果的交叉檢驗。這種混合方法確保了結論既能反映實際情況，又能體現技術嚴謹性，同時也能為產業、臨床和政策領域的決策者提供切實可行的指導。

摘要了綜合診斷、彈性供應鏈和相關人員協作將如何定義下一階段的獸用抗菌藥物管理和有效性檢測。

總之，獸用抗菌藥物敏感性檢測正處於曲折點，其特點是技術進步、採購動態變化以及對數據主導管理的日益成長的期望。表現型和分子方法的並存為改進臨床決策和監測提供了互補的管道，而數位整合則增強了將孤立的檢測結果轉化為縱向資訊的能力。然而，與樣本變異性、物種特異性驗證和供應鏈脆弱性相關的挑戰仍然突出，需要製造商、檢測實驗室和政策制定者共同應對。

未來的成功取決於務實的策略，這些策略需要將產品創新與不同獸醫環境的營運實際情況結合。加強在地化生產、改進技術支援以及實施可互通的軟體解決方案，將減少終端用戶的摩擦，並在面臨財務和物流壓力時保障檢測的連續性。同樣重要的是，相關人員應攜手合作，協調驗證標準，並確保診斷結果能夠轉化為有效的抗菌藥物管理措施，從而保護動物和公眾健康。

最終，診斷界有機會透過優先考慮準確性、可近性和可操作的數據流，在治療效果和抗藥性抑制方面取得可衡量的進展。如此一來，相關人員便能確保抗菌藥物的長期有效性，並支持能夠有效應對不斷演變的微生物威脅的、具有韌性的動物健康系統。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將快速分子診斷技術整合到農場獸醫藥敏試驗工作流程中，以縮短週轉時間
  • 推出一款可攜式照護現場（POC​​）抗菌藥物敏感性檢測設備，用於偏遠農場的牲畜健康管理
  • 開發專門針對臨床環境中獸醫細菌分離株的自動化、高性能表現型藥敏試驗平台
  • 實施人工智慧驅動的預測分析工具，以監測動物健康領域抗菌素抗藥性的趨勢
  • 擴展多重PCR檢測板，用於同時檢測和定量伴侶動物病原體中的多種抗藥性基因
  • 基於農場特定藥敏試驗數據的個人化抗菌藥物管理方案的出現，旨在遏制獸用抗生素的濫用。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測類型分類的動物抗菌藥物敏感性檢測市場

  • 自動化系統
    • 微型掃描系統
    • 鳳凰系統
    • VITEK系統
    • 離開系統
  • 肉湯微量稀釋法
    • 自動培養基微量稀釋
    • 手動肉湯微量稀釋法
  • 紙錠擴散法
  • ETEST
  • 分子方法
    • 基於LAMP的方法
    • 基於NGS的方法
    • 基於PCR的方法
    • 基於qPCR的方法

9. 依動物類型分類的動物抗菌藥物敏感性測試市場

  • 水產養殖
  • 伴侶動物
  • 馬
  • 家畜
  • 家禽

第10章 以最終用戶分類的動物抗菌藥物敏感性測試市場

  • 製藥和生物技術
  • 研究所
  • 獸醫診斷實驗室
  • 獸醫醫院和診所

第11章 依病原體類型分類的動物抗菌藥物敏感性測試市場

  • 真菌
  • 革蘭氏陰性菌
  • 革蘭氏陽性菌
  • 結核分枝桿菌

第12章：按樣本類型分類的動物抗菌藥物敏感性測試市場

  • 血
  • 牛奶
  • 棉花棒
  • 組織
  • 尿

第13章 動物抗菌藥物敏感性測試市場（依產品類型分類）

  • 裝置
    • 自動化設備
    • 桌面設備
  • 套件和試劑
    • 消耗品
    • 試劑
  • 軟體和服務
    • 資料管理軟體
    • 技術支援和諮詢

14. 各地區獸用抗菌藥物敏感性檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 動物抗菌藥物敏感性測試市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國動物抗菌藥物敏感性測試市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Becton, Dickinson and Company
    • IDEXX Laboratories, Inc.
    • Bruker Corporation
    • Creative Diagnostics
    • Merck & Co., Inc.
    • Eurofins Scientific SE
    • SGS SA
    • Bio-Rad Laboratories
Product Code: MRR-FD3F12D533B4

The Veterinary Antimicrobial Susceptibility Testing Market is projected to grow by USD 221.88 million at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 113.38 million
Estimated Year [2025] USD 123.33 million
Forecast Year [2032] USD 221.88 million
CAGR (%) 8.75%

Contextualizing veterinary antimicrobial susceptibility testing within clinical practice, laboratory operations, and the broader One Health imperative to guide timely and responsible interventions

The evolution of antimicrobial resistance in animal health demands a clear, evidence-driven introduction that frames the role of diagnostic testing in preserving therapeutic efficacy and safeguarding both animal and public health. Veterinary antimicrobial susceptibility testing operates at the intersection of clinical decision-making, surveillance, and regulatory oversight, and its effective deployment influences treatment outcomes, antimicrobial stewardship programs, and the detection of emerging resistance mechanisms. As diagnostic capabilities advance, laboratories and clinicians must adopt workflows and technologies that deliver reliable, reproducible results within clinically actionable timeframes.

The introduction to this landscape recognizes the heterogeneity of veterinary practice, from high-throughput diagnostic laboratories servicing livestock operations to point-of-care testing in companion animal clinics and aquaculture settings. Differences in species biology, sample matrices, and pathogen diversity create unique analytical challenges that require tailored methodologies and interpretive criteria. Consequently, laboratory directors and policy-makers must balance considerations of accuracy, turnaround time, cost, and regulatory compliance when selecting testing platforms and protocols.

Moreover, the integration of molecular methods alongside phenotypic assays has reshaped diagnostic pathways. Molecular approaches enable rapid detection of resistance determinants and outbreak-related genotypes, while traditional broth microdilution and disk diffusion remain the clinical standards for phenotypic susceptibility interpretation. This introduction underscores the imperative for cross-disciplinary collaboration among veterinarians, microbiologists, epidemiologists, and industry partners to translate diagnostic innovation into sustained improvements in antimicrobial stewardship and animal health outcomes.

How technological innovation, regulatory evolution, and digital integration are reshaping veterinary susceptibility testing and accelerating clinical and surveillance capabilities

Transformative shifts in veterinary antimicrobial susceptibility testing reflect technological innovation, shifting regulatory expectations, and evolving clinical needs that together are redefining diagnostic pathways. Automated systems are improving throughput and standardization, enabling laboratories to scale operations while reducing variability in susceptibility interpretation. Concurrently, rapid molecular techniques and next-generation sequencing are expanding the ability to detect resistance determinants and trace transmission, thus enhancing surveillance capacity and informing targeted interventions.

Industry adoption is further influenced by digital transformation, with data management software and integrated informatics platforms supporting interpretive consistency, reporting, and longitudinal surveillance. These tools facilitate the aggregation of susceptibility data across facilities and species, which strengthens regional and national antimicrobial stewardship initiatives. At the same time, regulatory bodies and professional societies are intensifying guidance on interpretive criteria and validation standards, prompting laboratories to re-evaluate workflows and ensure compliance with evolving quality frameworks.

Economic and operational pressures are catalyzing changes in market behavior. End users demand solutions that balance accuracy and speed with cost-effectiveness, leading to a diversification of offerings across automated instruments, bench-top systems, and modular kits. As a result, manufacturers and service providers are increasingly focused on interoperability, remote support, and tailored reagent systems that address the practical realities of veterinary testing environments. Together, these shifts are driving a more connected, responsive diagnostic ecosystem capable of supporting both clinical care and public health objectives.

Assessing the operational and procurement consequences of 2025 tariff adjustments on diagnostic equipment, consumables, and laboratory supply chain resilience

Tariff changes enacted in 2025 have introduced a new layer of complexity for stakeholders procuring diagnostic instruments, consumables, and reagents internationally. Increased duties on certain imported laboratory equipment and components have created cost pressures that affect procurement strategies for veterinary diagnostic laboratories, manufacturers of instruments, and distributors of consumables. These fiscal shifts have prompted organizations to reassess supplier relationships, inventory strategies, and capital investment timelines to mitigate near-term budgetary impacts.

In response, several laboratories and end users are prioritizing local sourcing where feasible, engaging with regional manufacturers to diversify supply chains and reduce exposure to tariff volatility. This has accelerated conversations around regional manufacturing capacity and the localization of critical consumables such as broth microdilution panels, disk diffusion supplies, and molecular assay reagents. Simultaneously, procurement teams are evaluating total cost of ownership, including logistics, customs processing, and potential delays, to inform purchasing cycles and service-level agreements.

On the supplier side, manufacturers are exploring strategic responses that include partial regional manufacturing, pricing rebates, and bundled service offerings to preserve market access. These adaptations aim to sustain adoption rates of automated systems and molecular platforms by minimizing direct cost pass-throughs to end users. Importantly, the tariff environment has highlighted the need for more robust risk assessment frameworks within laboratory procurement processes, emphasizing contingency planning and collaborative approaches that protect testing continuity while managing fiscal constraints.

Dissecting how test modalities, species-specific needs, end users, pathogen diversity, sample matrices, and product categories converge to define diagnostic priorities and investment strategies

Segment-level dynamics illuminate how different test modalities, animal populations, end users, pathogen groups, sample matrices, and product categories shape diagnostic demand and innovation priorities. Test type distinctions span Automated Systems, Broth Microdilution, Disk Diffusion, Etest, and Molecular Methods, with Automated Systems further differentiated by platforms such as MicroScan, PHOENIX, VITEK, and WalkAway systems. Broth microdilution is bifurcated into automated and manual formats, while molecular modalities encompass LAMP-based methods, NGS-based strategies, PCR, and qPCR, each offering distinct trade-offs between speed, sensitivity, and informational depth.

Animal type segmentation covers aquaculture, companion animals, equine, livestock, and poultry, highlighting how disease prevalence, husbandry practices, and regulatory frameworks vary across species and influence testing workflows. End users range from pharmaceutical and biotech companies to research institutes, veterinary diagnostic laboratories, and veterinary hospitals and clinics, and each of these stakeholders exhibits unique priorities: pharmaceutical developers emphasize standardized AST data for drug development, research institutes focus on method development and epidemiology, diagnostic laboratories prioritize throughput and quality control, and clinical settings require rapid, actionable results.

Pathogen type divides into fungi, Gram-negative bacteria, Gram-positive bacteria, and mycobacteria, which necessitates distinct panels, interpretive criteria, and containment practices. Sample types such as blood, milk, swab specimens, tissue, and urine impose diverse pre-analytical challenges that influence assay selection and validation needs. Product-type segmentation spans instruments, kits and reagents, and software and services; instruments are further categorized into automated and bench-top systems, kits and reagents into consumables and reagents, and software and services into data management software and technical support and consulting. These intersecting segments drive differential investment patterns, validation requirements, and market entry strategies, and they underscore the importance of modular product design, robust supply chains, and targeted customer support to meet the varied demands of the veterinary diagnostic community.

Regional diagnostic adoption is driven by infrastructure, regulatory frameworks, and species-specific priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Regional patterns underscore how geography, regulatory context, and industry infrastructure shape adoption of antimicrobial susceptibility testing solutions. In the Americas, advanced laboratory networks and established veterinary clinical practices support early adoption of automated instruments and integrated informatics, while regional initiatives emphasize surveillance data aggregation and stewardship programs that connect clinical laboratories with public health systems. Investment in veterinary diagnostics is visible across companion animal and livestock sectors, driven by a combination of private laboratory consolidation and sector-specific regulatory attention.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts and laboratory accreditation frameworks are generating demand for standardized testing protocols and interoperable data systems. Northern and Western European markets exhibit high uptake of molecular diagnostics and automated platforms, supported by robust surveillance infrastructures, whereas other subregions focus on capacity building and access to reliable consumables. Meanwhile, the Middle East and Africa are prioritizing scalable, cost-effective solutions that address logistical constraints and species diversity across varying husbandry systems.

Asia-Pacific remains a dynamic region with growing manufacturing capabilities and a strong emphasis on aquaculture and livestock diagnostics, reflecting the region's agricultural footprint. Rapid urbanization and rising companion animal ownership in certain markets are creating parallel demand for clinical-grade diagnostics. Across these regions, cross-border trade, regional manufacturing, and evolving regulatory requirements are prompting manufacturers and laboratories to adopt flexible distribution models and localized support strategies to ensure consistent testing quality and supply reliability.

How vendors are combining validated platforms, localized support, and integrated data analytics to deliver resilient diagnostic solutions and long-term customer partnerships

Leading organizations in the veterinary antimicrobial susceptibility testing space are differentiating through platform breadth, regional reach, and service capabilities that address both routine diagnostic needs and complex surveillance requirements. Manufacturers that combine validated automated instruments with robust reagent supply chains and data management software have an advantage in supporting high-throughput laboratories seeking to standardize workflows. At the same time, companies that invest in modular bench-top platforms and specialized kits are well positioned to serve decentralized clinical settings and species-specific testing demands.

Service and support offerings play a critical role in maintaining instrument uptime and ensuring interpretive consistency across sites. Technical support, training programs, and consulting services that assist laboratories with validation, quality assurance, and regulatory compliance enhance customer retention and create opportunities for long-term partnerships. Collaborative engagements with research institutes and pharmaceutical developers further strengthen product pipelines and phase-in of new methodologies, especially for emerging resistance mechanisms.

Strategic differentiation also extends to software and analytics capabilities. Providers that enable integrated data management, automated reporting, and trend analysis help laboratories convert raw susceptibility data into actionable intelligence for clinicians and stewardship committees. Companies leveraging partnerships to expand regional manufacturing and distribution networks are better equipped to respond to supply chain disruptions and tariff impacts, thereby preserving market access and supporting consistent testing availability for end users.

Practical strategic moves for vendors and laboratories to strengthen diagnostic performance, supply resilience, and integrated data capabilities in support of stewardship objectives

Industry leaders should prioritize investments that strengthen diagnostic accuracy, supply resilience, and actionable data workflows to meet clinical and surveillance needs. First, aligning platform portfolios with end-user operational realities-by offering both high-throughput automated systems and flexible bench-top solutions-will allow providers to serve the full spectrum of laboratory environments and clinical contexts. Complementing hardware with reliable kits, reagents, and quality control materials reduces barriers to adoption and supports reproducible results across sites.

Second, expanding regional manufacturing and logistics capabilities will mitigate exposure to tariff-related cost volatility and geopolitical supply disruptions. Establishing localized reagent production, strategic distribution partnerships, and inventory buffering strategies will protect continuity of testing services. Third, investing in data management software and interoperability increases the value proposition for end users by enabling integrated reporting, trend analysis, and data sharing for stewardship and surveillance purposes. This approach fosters stronger ties with laboratories and policy stakeholders while creating new revenue streams linked to analytics and advisory services.

Finally, industry players should deepen engagement with regulators, professional societies, and veterinary networks to align assay validation, interpretive criteria, and reporting standards. Proactive collaboration will accelerate adoption of innovative methods, ensure compliance with evolving guidelines, and support the translation of diagnostic data into effective stewardship policies. Collectively, these recommendations encourage a balanced strategy that emphasizes technological excellence, operational resilience, and stakeholder collaboration to drive sustainable outcomes.

A mixed-methods approach combining expert interviews, technical literature review, and product landscape analysis to produce actionable and rigorously validated diagnostic insights

This research synthesis draws on a multidimensional methodology that combines primary qualitative engagement with domain experts, secondary literature review, and product landscape analysis to build a comprehensive understanding of the veterinary antimicrobial susceptibility testing environment. Primary inputs include structured interviews with laboratory directors, clinical veterinarians, procurement specialists, and industry executives to capture operational priorities, validation practices, and procurement behaviors. These conversations prioritize insights into real-world workflows and the practical trade-offs laboratories make between speed, accuracy, and cost.

Secondary research canvassed peer-reviewed scientific publications, regulatory guidance documents, and public surveillance reports to ensure technical accuracy in describing methodologies, interpretive criteria, and pathogen-specific testing considerations. Product landscape analysis involved cataloging instrument platforms, assay formats, reagent systems, and software offerings to map functional capabilities and service models. Throughout, attention was paid to validation requirements, quality management practices, and the implications of regulatory frameworks across jurisdictions.

Data synthesis integrated qualitative findings with product and regional analyses to identify key trends, operational challenges, and strategic opportunities. Cross-validation of insights was achieved by triangulating perspectives from multiple stakeholder groups and by assessing consistency with documented regulatory developments and peer-reviewed evidence. This mixed-methods approach ensures that conclusions reflect practical realities and technical rigor while remaining actionable for decision-makers across industry, clinical, and policy domains.

Summarizing how integrated diagnostics, resilient supply chains, and stakeholder collaboration will define the next phase of veterinary antimicrobial stewardship and testing effectiveness

In conclusion, veterinary antimicrobial susceptibility testing is at an inflection point characterized by technological advancement, shifting procurement dynamics, and heightened expectations for data-driven stewardship. The coexistence of phenotypic and molecular approaches offers complementary pathways to improve clinical decision-making and surveillance, while digital integration enhances the ability to transform isolated test results into longitudinal intelligence. However, challenges related to sample diversity, species-specific validation, and supply chain vulnerabilities remain salient and require coordinated responses from manufacturers, laboratories, and policy-makers.

Moving forward, success will depend on pragmatic strategies that align product innovation with the operational realities of diverse veterinary settings. Strengthening regional manufacturing, enhancing technical support, and deploying interoperable software solutions will reduce friction for end users and protect testing continuity in the face of fiscal and logistical pressures. Equally important is collaborative engagement across stakeholders to harmonize validation standards and ensure that diagnostic outputs are translated into effective antimicrobial stewardship actions that protect both animal and public health.

Ultimately, the diagnostic community has an opportunity to deliver measurable improvements in treatment outcomes and resistance containment by prioritizing accuracy, accessibility, and actionable data flows. By doing so, stakeholders can help secure the long-term effectiveness of antimicrobials and support resilient animal health systems that respond efficiently to evolving microbial threats.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid molecular diagnostics into on-farm veterinary AST workflows to reduce turnaround time
  • 5.2. Adoption of portable point-of-care antimicrobial susceptibility testing devices for livestock health management in remote farms
  • 5.3. Development of automated high-throughput phenotypic AST platforms designed specifically for veterinary bacterial isolates in clinical settings
  • 5.4. Implementation of artificial intelligence driven predictive analytics tools for monitoring antimicrobial resistance trends in animal health
  • 5.5. Expansion of multiplex PCR panels for simultaneous detection and quantification of multiple resistance genes in companion animal pathogens
  • 5.6. Emergence of personalized antimicrobial stewardship programs based on farm specific AST data to curb veterinary antibiotic misuse

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Antimicrobial Susceptibility Testing Market, by Test Type

  • 8.1. Automated Systems
    • 8.1.1. MicroScan Systems
    • 8.1.2. PHOENIX Systems
    • 8.1.3. VITEK Systems
    • 8.1.4. WalkAway Systems
  • 8.2. Broth Microdilution
    • 8.2.1. Automated Broth Microdilution
    • 8.2.2. Manual Broth Microdilution
  • 8.3. Disk Diffusion
  • 8.4. Etest
  • 8.5. Molecular Methods
    • 8.5.1. LAMP-Based Methods
    • 8.5.2. NGS-Based Methods
    • 8.5.3. PCR-Based Methods
    • 8.5.4. QPCR-Based Methods

9. Veterinary Antimicrobial Susceptibility Testing Market, by Animal Type

  • 9.1. Aquaculture
  • 9.2. Companion Animals
  • 9.3. Equine
  • 9.4. Livestock
  • 9.5. Poultry

10. Veterinary Antimicrobial Susceptibility Testing Market, by End User

  • 10.1. Pharma And Biotech
  • 10.2. Research Institutes
  • 10.3. Veterinary Diagnostic Laboratories
  • 10.4. Veterinary Hospitals And Clinics

11. Veterinary Antimicrobial Susceptibility Testing Market, by Pathogen Type

  • 11.1. Fungi
  • 11.2. Gram-Negative Bacteria
  • 11.3. Gram-Positive Bacteria
  • 11.4. Mycobacteria

12. Veterinary Antimicrobial Susceptibility Testing Market, by Sample Type

  • 12.1. Blood
  • 12.2. Milk
  • 12.3. Swab
  • 12.4. Tissue
  • 12.5. Urine

13. Veterinary Antimicrobial Susceptibility Testing Market, by Product Type

  • 13.1. Instruments
    • 13.1.1. Automated Instruments
    • 13.1.2. Bench-Top Instruments
  • 13.2. Kits And Reagents
    • 13.2.1. Consumables
    • 13.2.2. Reagents
  • 13.3. Software And Services
    • 13.3.1. Data Management Software
    • 13.3.2. Technical Support And Consulting

14. Veterinary Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. bioMerieux SA
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. IDEXX Laboratories, Inc.
    • 17.3.5. Bruker Corporation
    • 17.3.6. Creative Diagnostics
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Eurofins Scientific SE
    • 17.3.9. SGS SA
    • 17.3.10. Bio-Rad Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTIMICROBI